Biosynex has acquired Para’kito
Biosynex has acquired Para’kito, operated by Hong-Kong based Evergreen Land Ltd. The transaction includes assets and IP and the exclusive right to commercialize the brand in Europe, Africa and South America.
Created in 2005, Biosynex is a leading public health player in France and Europe. The group develops, manufactures and markets medical devices for screening, diagnosis and prevention. Biosynex is the French market leader in the design and distribution of rapid tests (RDT), commercialized in 90+ countries. The company provides its products to biology and medical analysis laboratories, hospitals, pharmacies, resellers and department stores. In 2021, the group generated over US$400 million of sales.
Launched in 2008, Para’kito is the leading European brand in the prevention and care of mosquito bites. The company provides a complete range of anti-mosquito bracelets and sprays based on 100% natural formulas, with a proprietary technology, and distributed via two channels: pharmacies and e-commerce. Para’kito is present in more than 30 countries and supplies 5,000+ pharmacies in France. In 2021, the brand generated over US$7 million of sales in Europe.
Oaklins’ team in France acted as M&A advisor to Biosynex in this transaction.
![](/api/deal-hero-image/108182/deal-hero-image.jpg)
![](/api/deal-party-images/108182/deal-parties.png)
Talk to the deal team
Related deals
Leika Medical Equipments Ltd. has been acquired by Angus Capital
The shareholders of Leika Medical Equipments Ltd. have sold the company to Angus Capital.
Learn morePhen’X Technologies has sold a majority stake to Ciclad
The shareholders of Phen’X Technologies have completed a primary majority LBO with private equity fund Ciclad.
Learn moreMedis Medical Imaging and GE HealthCare announce collaboration focused on non-invasive coronary assessments
Medis Medical Imaging Systems B.V., a leading cardiac imaging software company, have completed a strategic investment to further develop its revolutionary non-invasive cardiovascular imaging solution. The company has announced its collaboration with GE HealthCare (Nasdaq: GEHC), a global leader in medical technology, pharmaceutical diagnostics and innovation in digital solutions, to contribute to the advancement of precision care in the diagnosis and treatment of coronary artery disease (CAD).
Learn more